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The positive association between body weight and bone density has been established in
numerous laboratory and clinical studies. Apart from the direct effect of soft tissue mass on
bone through skeletal loading, a number of cytokines and hormones contribute to the pos-
itive association between adipose and bone tissue, acting either locally in sites where cells
of the two tissues are adjacent to each other or systemically through the circulation. The
current review describes the effects of such local and systemic factors on bone physiology.
One class of factors are the adipocyte-secreted peptides (adipokines), which affect bone
turnover through a combination of direct effects in bone cells and indirect mechanisms
mediated by the central nervous system. Another source of hormones that contribute to
the coupling between fat and bone tissue are beta cells of the pancreas. Insulin, amylin,
and preptin are co-secreted from pancreatic beta cells in response to increased glucose
levels after feeding, and are also found in high circulating levels in obesity. A number of
peptide hormones secreted from the gastrointestinal tract in response to feeding affect
both fat and bone cells and thus can also act as mediators of the association between
the two tissues. The current review focuses on results of laboratory studies investigating
possible mechanism involved in the positive association between fat mass and bone mass.
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INTRODUCTION
The skeleton provides structural support to soft tissues, attach-
ment sites for muscles, and protection of vital organs. In addition,
bone tissue acts as a reservoir for ions that can be sequestered from
or released into the serum as required for the maintenance of cal-
cium and phosphate homeostasis. Complex regulatory networks
control bone physiology and optimize the response of bone to the
changing mechanical and metabolic requirements (1, 2). The size
and strength of the skeleton is adjusted to the mass of soft tissue
to provide optimal support without being heavier than necessary
and the rate of bone turnover has to be constantly adjusted to the
availability of nutrients and the levels of circulating calcium and
phosphate.
Body weight is positively correlated with bone mineral density
(BMD) and negatively correlated with fracture risk (3). In con-
trast to the consistent finding that underweight is a major risk
factor for fracture, the protective effect of increased weight against
fracture appears to be more complex. Thus, when analyzing the
contribution of the two components of body weight; fat mass and
lean mass to the correlation with BMD, most studies identify fat
mass as the major contributing factor while some studies find sig-
nificant correlation with lean mass (4–6). Differential effects of
visceral and subcutaneous fat have also been described, suggest-
ing that subcutaneous fat is beneficial to bone whereas visceral
fat is deleterious (7, 8). In addition, there is evidence that the
relationship between weight and fracture risk is site-specific (9).
A recently published study of the relationship of weight, height,
and body mass index (BMI) with fracture risk at different sites in
post-menopausal women found a significant inverse association
between BMI and hip, spine, and wrist fractures and positive asso-
ciation between weight and ankle fractures (10). The effect of body
weight on fracture risk also appears to be age-dependent, as obe-
sity is a risk factor for fracture in children but is protective in
adults (7).
Obesity is considered a global epidemic with serious co-
morbidities that include type-2 diabetes, hypertension, and cancer
(11). A number of clinical studies of the relationship between fat
and bone mass and fracture risk in obese people demonstrated
that the higher BMD in obesity is not as protective against frac-
tures as it is in people with normal BMI (12). During the past
two decades, the various procedures of bariatric surgery have
increasingly become a common treatment for obesity (11). Both
the weight gain in obesity and the rapid weight loss follow-
ing bariatric surgery have major impacts on the skeleton, and
many aspects of the relationship among nutritional status, fat
tissue, and the skeleton have been studied in these conditions
(11, 13–16).
In recent years, the traditional distinction between endocrine
organs and target tissues has become blurred as it is now clear
that many tissues secrete factors that circulate and act on target
organs, thus creating complex communication networks where
many tissues have endocrine functions. In the crosstalk between
fat and bone, there is a major role for circulating factors secreted
from adipose tissue; adipokines, as well as factors secreted from
beta cells of the pancreas and from the gastrointestinal tract in
response to feeding. The current review focuses on the bone activ-
ities of the local and circulating factors, which generate the positive
association between fat and bone.
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ADIPOKINES
Adipokines are regulatory factors secreted from adipocytes that
reside within adipose tissue and in the bone marrow. Several
adipokines have been studied extensively and their effects in bone
and other tissues are well-described, whereas the activities of
additional novel adipokines are still largely unknown.
LEPTIN
The endocrine function of fat tissue was first discovered with
the cloning of leptin and the finding that leptin is secreted from
adipocytes and is part of a negative feedback loop that regulates
fat tissue mass (17). Circulating levels of leptin positively corre-
late with body fat and its primary target in the regulation of fat
mass was identified as the hypothalamus, where leptin binds to
its receptor and regulates appetite and energy expenditure (18).
Consequent studies showed a wide distribution of leptin receptors
outside the central nervous system, and the expression of the sig-
naling form of the leptin receptor in osteoblasts and chondrocytes
suggested the skeleton as a potential target (19–21). The effects of
leptin on bone mass are complex, with a combination of direct
activity in bone cells, indirect effects through the central nervous
systems as well as secondary effects through changes in body mass,
and levels of other circulating hormones.
The direct effects of leptin in bone cells are anabolic. Leptin
increases proliferation and differentiation of osteoblasts and chon-
drocytes (19–22) and reduces osteoclastogenesis through inhibit-
ing the expression of receptor activator of nuclear factor κB ligand
(RANKL) and induction of osteoprotegerin (19, 23). These results
suggest that leptin has an overall positive effect on bone, and could
therefore be a possible mediator of the positive correlation between
fat and bone tissue.
A number of groups studied the phenotype of leptin-deficient
mice (ob/ob) and leptin receptor-deficient mice (db/db), but the
results of these studies are sometimes conflicting, possibly due to
the different skeletal sites investigated and the specific parameters
measured (1, 3, 24). The two animal models show profound obe-
sity with reduced trabecular bone volume and BMD in femora and
tibiae and an increase in the number and size of adipocytes in the
marrow (25, 26). Systemic administration of leptin has an overall
positive effect on bone; injection into ob/ob mice led to an increase
in BMD (21, 25), while in wild-type mice leptin injection increased
bone strength in males (26) and reduced ovariectomy-induced
bone loss in females (27).
In contrast to these studies, Ducy et al. (28) found that circulat-
ing leptin inhibits bone formation via the hypothalamus and the
sympathetic nervous system. They reported that both ob/ob and
db/db mice have increased bone formation that results in high ver-
tebral bone mass, and that intracerebroventricular (ICV) infusion
of leptin causes bone loss in leptin-deficient and in wild-type mice
through inhibition of bone formation and stimulation of bone
resorption.
The main difference between the studies that show anabolic
activity of leptin in bone and the one that demonstrate catabolic
effects is the difference in the way leptin was administered: sys-
temically in the former and centrally into the brain in the latter.
However, Bartell et al. (29) directly compared the effect of leptin
injected SC or through ICV infusion and found that regardless
of the way of administration, leptin decreased body weight, food
intake, and body fat and increased BMD. Thus, the exact nature of
leptin activity in bone remains controversial and requires further
investigations (30).
Clinical studies of the effect of leptin in bone are inconclusive,
with some finding a positive correlation between leptin serum lev-
els and BMD (31, 32) and others finding no correlation (33–35).
Circulating leptin levels were not associated with fracture risk in a
large prospective cohort study (36).
ADIPONECTIN
Adiponectin, produced almost exclusively by adipocytes, is a
28 kDa protein that circulates in humans in trimers, hexamers,
and high-molecular weight oligomers, in total concentrations of
0.5–30µg/mL (37–39). Adiponectin regulates energy homeosta-
sis, glucose and lipid metabolism, and inflammatory pathways
(40). Plasma concentrations of adiponectin are inversely related
to visceral fat mass and BMI, possibly due to the inhibition
of adiponectin secretion by cytokines and hormones that are
increased in obesity, by adipose tissue hypoxia, or by a nega-
tive effect of adiponectin on its own production (37). Clinical
studies consistently show inverse relationships between circulat-
ing adiponectin concentrations and BMD, which persist after
adjustment for potential confounding factors, including BMI,
serum leptin, and central fat mass (33, 36, 41–43). There is a
suggestion that an increased level of circulating adiponectin is
a risk factor for fracture independent of body composition and
BMD (36).
The results of laboratory studies investigating the activity of
adiponectin in bone are not entirely congruent, but there is ample
evidence that adiponectin affects bone through a combination of
direct and indirect mechanisms. The direct activity of adiponectin
in bone cells is mediated through the AdipoR1 and AdipoR2
receptors, which are expressed in both osteoblasts and osteoclasts
(44, 45). In vitro, most groups found that adiponectin stimulates
the proliferation and differentiation of osteoblastic cells (46–48),
whereas studies of the effect of adiponectin on osteoclastogene-
sis produced conflicting results. Inhibition of osteoclastogenesis
was determined in bone marrow cultures (47, 48) while induc-
tion of osteoclastogenesis was found in co-cultures of osteoblasts
and CD14 positive cells from peripheral blood (49). Two groups
reported a direct inhibitory effect of adiponectin on osteoclast
formation in CD14 positive cells and in RAW264.7 cells (47,
50), whereas two studies that used similar experimental systems
showed no effects (48,49). The inconsistency of some of the in vitro
data could be explained by the finding that commercially available
preparations of adiponectin are contaminated with lipopolysac-
charide, and that this contaminant is responsible for some of the
reported in vitro effects observed (51, 52).
A number of animal models were used to investigate
adiponectin activity in bone. Adiponectin-deficient mice showed
no significant abnormality in bone phenotype at 8 weeks of age
(48, 53), but at 14 weeks, micro-computed tomography demon-
strated increase in trabecular bone volume and trabecular number
(48). Transgenic mice over-expressing adiponectin in the liver
showed no bone abnormality (53), whereas in another study tran-
sient over-expression of adiponectin in mice increased trabecular
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bone mass and reduced osteoclast number and bone resorption
(50). A recent in vivo study showed that the effects of adiponectin
in bone are age-dependent (54). In young animals, the domi-
nant effect of adiponectin is the attenuation of bone formation
through inhibition of osteoblast proliferation and induction of
their apoptosis, whereas in older animals, these local effects are
masked by the activity of adiponectin to decrease the sympa-
thetic tone, indirectly leading to an increase in bone mass. Thus,
according to this study, adiponectin has both positive and neg-
ative effects on bone mass and adiponectin-deficient mice show
increase in bone mass at a young age and an osteoporotic phe-
notype at 36 weeks (54). In another recent study, Wang et al.
(55) compared the effect of ovariectomy on BMD and biome-
chanical strength in wild-type and adiponectin-deficient mice.
The study showed that adiponectin-deficiency protects against
ovariectomy-induced osteoporosis in mice, and suggested that a
possible underlying mechanism for that effect is the enhanced
osteogenic differentiation of mesenchymal stem cells identified in
the adiponectin-deficient mice.
OTHER ADIPOKINES
Resistin, fasting-induced adipose factor (FIAF), visfatin, vaspin,
and apelin have been identified in recent years as additional
factors secreted from adipocytes (56). Only a few clinical stud-
ies investigated the relationship between circulating levels of
these factors and BMD, and studies of their activities in bone
cells in vitro are still in preliminary stages. Most of the clini-
cal studies that investigated the relationship between a number
of the adipokines, including apelin, resistin, and visfatin and
BMD found no significant correlations (34, 35, 57). A systematic
review and meta-analysis found no association between resistin
or visfatin and BMD and the authors concluded that inconsis-
tent associations between these adipokines and BMD are prob-
ably confounded by body composition, in particular fat mass
parameters (58).
The activities of FIAF, resistin, and visfatin in bone cells have
been studied in vitro. FIAF is cleaved in vivo into an N-terminal
coiled-coil domain [FIAF (CCD)] and a C-terminal fibrinogen-
like domain [FIAF (FLD)] (59, 60). FIAF (CCD) inhibited osteo-
clast differentiation and function in mouse primary bone marrow
and in RAW264.7 cell cultures, and decreased expression of genes
encoding key osteoclastogenic factors such as M-CSF, connective
tissue growth factor (CTGF), NFATc1, and DC-STAMP (61). FIAF
(FLD) and intact FIAF were without effect in these experimental
systems. In addition, FIAF (CCD) stimulated the proliferation of
rat primary osteoblasts, but had no effect on osteoblasts differ-
entiation. Thommesen et al. found that resistin is expressed in
primary human bone marrow stem cells and in mature human
osteoblasts (62). The expression of resistin mRNA in RAW 264.7
is increased during differentiation into mature osteoclasts, and
treatment with recombinant resistin increased the number of
differentiated osteoclasts in RAW 264.7 cells and enhanced the pro-
liferation of MC3T3-E1 osteoblast-like cells. Studies of visfatin, an
adipokine highly expressed in visceral fat and up-regulated in obe-
sity and type-2 diabetes, showed that it has insulin-mimetic effects
in various cell lines. In human primary osteoblasts, similar to
insulin, visfatin enhanced glucose uptake, proliferation, and type I
collagen synthesis (63). Further studies of the different adipokines
and their effects in bone in vitro and in vivo are required to deter-
mine their possible role in the positive association between fat and
bone.
BETA-PANCREATIC HORMONES
Insulin resistance in obesity leads to hypersecretion of insulin
from β-pancreatic cells and two other hormones co-secreted with
insulin, amylin, and preptin, also circulate at high levels in obesity.
As these threeβ-pancreatic hormones directly affect bone cells they
are likely to contribute to the fat mass/bone mass relationship.
INSULIN
A large number of clinical studied in women and men determined
that circulating insulin concentrations are related to BMD (64–
68). Osteoblasts express insulin and IGF-1 receptors and in vitro,
insulin directly stimulates osteoblast proliferation (69, 70). When
administered locally over the calvarias of adult male mice, insulin
produces two- to three-fold increases in histomorphometric
indices of bone formation (71).
In recent years, insulin signaling in bone was the focus of a
number of studies that proposed coupling between bone remod-
eling and glucose and energy metabolism mediated through an
endocrine function of bone cells (72–74). In rodent models,
insulin induces the expression of osteocalcin in osteoblasts, and
inhibits the expression of osteoprotegerin, therefore stimulating
osteoclast activity. Osteoclast-mediated resorption releases uncar-
boxylated osteocalcin into the circulation, where it ultimately
enhances pancreatic insulin production (73, 75). Uncarboxylated
osteocalcin is therefore a hormone secreted from bone, which acts
as a positive regulator of insulin secretion, and was also shown
to promote insulin sensitivity in peripheral tissues. However, the
relevance of these novel findings to human physiology is uncer-
tain. Antiresorptive therapies for osteoporosis reduce bone forma-
tion markers, including osteocalcin, and therefore patients treated
with these medications would be expected to have increased risk
for insulin resistance and diabetes. However, a post hoc analy-
sis of large randomized placebo-controlled trials of antiresorptive
therapies found that suppression of bone resorption, which sig-
nificantly reduces the level of circulating osteocalcin, does not
have a clinically important effect on fasting glucose or diabetes
incidence (76).
In addition to its direct activity in bone cells, insulin also affects
BMD indirectly, through increasing the levels of circulating sex
hormones and saturated fatty acids (1). Clinical studies show that
women with hyperinsulinemia have increased production estro-
gen and androgen in the ovary and reduced production of sex
hormone binding globulin in the liver. These indirect mecha-
nisms contribute to the high BMD in states of hyperinsulinemia,
including obesity and generalized lipodystrophy (1).
AMYLIN
Amylin is a peptide hormone that belongs to the calcitonin family
and is evolutionary related to insulin. In vitro, amylin directly
stimulates osteoblast proliferation (77) and inhibits osteoclast
differentiation and activity, although with lower potency than
calcitonin (78). Systemic administration of amylin substantially
www.frontiersin.org May 2014 | Volume 5 | Article 70 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Naot and Cornish Mediators of fat–bone association
increases bone volume in mice (79) and rats (80). In a study of
the osteogenic effects of amylin in OVX rats, amylin protected the
animals against OVX-induced bone loss at the distal metaphysis
and total femora (81). Higher circulating levels of osteocalcin and
lower levels of urinary deoxypyridinoline excretion in the amylin-
treated animals in comparison to OVX untreated rats, suggests
that amylin acts through the stimulation of osteoblast activity
as well as inhibition of bone resorption. A recent study tested
the osteogenic activity of amylin in normal rats, fructose-induced
insulin-resistant and streptozotocin-induced type-2 diabetic rats
(82). Infusion of amylin for 3 days had different outcomes in
the three groups of animals. In normal rats, amylin induced an
increase in bone formation rate and reduced osteoclast surface
and erosive surface in the femur, in type-2 diabetic rats amylin nor-
malized trabecular structure parameters and increased osteoblast
number, whereas in insulin-resistant rats amylin appeared to have
no osteogenic effects (82).
The phenotype of amylin-deficient mice was described by Dac-
quin et al. (83). In this model, amylin deficiency did not alter the
regulation of food intake, body weight, and glucose metabolism.
At the age of 24 weeks, amylin-deficient mice had a typical osteo-
porotic phenotype; showing decreased BMD of long bones, low
bone mass, and a 50% decrease in trabecular bone volume. The
number of osteoblasts and bone formation rate were similar in
amylin-deficient mice and wild-type controls, suggesting that the
osteoporotic phenotype was not a result of a defect in bone for-
mation. The amylin-deficient mice had an increased number of
osteoclasts and an increase in degradation products of collagen in
the urine, suggestive of accelerated bone resorption. Further stud-
ies of amylin-deficient mice demonstrated that the bone effects
were sex-dependent. Amylin-deficient males showed increased
trabecular thickness at 4 and 6 weeks of age and increased femoral
length at 26 weeks, whereas female mice were no different than the
wild type (84).
Only a small number of studies investigated the bone effects of
amylin in humans. In a study of 16 women with anorexia nervosa
and 15 healthy controls, Wojcik et al. found that amylin levels were
positively associated with BMD and Z -scores at the femoral neck
and total hip, and the association remained significant after con-
trolling for weight or fat mass (85). In addition, the study found
that women with anorexia nervosa had significantly lower levels of
fasting amylin, suggesting that amylin could be one of the mech-
anisms underlying bone loss in anorexia nervosa (85). In another
study, a group of patients with type 1 diabetes were treated with
pramlintide (amylin analog) for 12 months (86). Although these
patients were expected to benefit from the therapy due to the
chronic amylin deficiency associated with diabetes, no change in
BMD or biochemical markers of bone metabolism was observed
following the treatment.
PREPTIN
Preptin, a peptide that corresponds to Asp69–Leu102 of pro-
insulin-like growth factor-2 (pro-IGF-2), was identified as an addi-
tional molecule stored in secretory vesicles of pancreatic beta cells,
and co-secreted with insulin and amylin (87). Preptin increases
glucose-mediated insulin secretion (87). Circulating levels of
preptin were found to be higher in diabetic patients compared to
patients with impaired glucose tolerance and controls, suggesting
a potential role for preptin in the pathogenesis of type-2 dia-
betes mellitus (88). Similar to the other beta-pancreatic hormones,
preptin has anabolic activity in bone.
In vitro studies demonstrated that preptin stimulates the pro-
liferation of primary rat osteoblasts and osteoblast-like cell lines
and reduces osteoblast apoptosis induced by serum deprivation
(89). Preptin-induced phosphorylation of p42/p44 MAP kinases
in osteoblastic cells and its proliferative effects were blocked
by MAP kinase inhibitors (89). In human primary osteoblasts,
preptin promoted proliferation and alkaline phosphatase activ-
ity through induction of p42/p44 MAP kinase and CTGF (90).
Preptin did not affect bone resorption in mouse bone marrow
cultures (89). In contrast, a recent study that compared the effect
of IGF-I, IGF-II, insulin, and preptin on human bone cells, sug-
gested that preptin induces differentiation and activity of both
osteoblasts and osteoclasts (91). In vivo, local administration of
preptin increased bone formation and bone area in adult male
mice (89).
Indications for the anabolic effect of preptin on bone in humans
arise from a number of clinical observations. Increased circulating
levels of a pro-IGF-2-(89-101) peptide in complex with IGF-
binding protein-2 have been implicated in osteosclerosis observed
in a number of patients with chronic hepatitis C infections (92).
Patients with excess of other forms of pro-IGF-2, which do not
contain the preptin sequence, do not develop osteosclerosis. A
recent study measured preptin levels and bone metabolic markers
in serum samples from male patients with osteoporosis, osteope-
nia, and normal bone mass (93). Serum preptin levels were lowest
in the osteoporosis group, and were positively correlated with
bone formation markers, whereas no correlation was observed
with markers of bone resorption.
GASTROINTESTINAL HORMONES
Diet plays a critical role in mineral homeostasis as bone turnover
is acutely responsive to food intake (94, 95). Feeding results in a
decrease of up to 50% in markers of bone resorption and a more
modest decrease in markers of bone formation (94, 96). Markers
of bone resorption decrease 20 min after food intake and return to
baseline after 6 h. In a study of controlled food intake over 5 days,
a 70% energy restriction produced about 30% decrease in mark-
ers of bone formation and a similar increase in markers of bone
resorption (97). A number of peptide hormones secreted from
the gastrointestinal tract in response to feeding affect bone tissue,
either directly or indirectly, and thus contribute to the coupling
between feeding status and bone turnover.
GHRELIN
Ghrelin, a growth hormone (GH) secretagogue, is a peptide hor-
mone primarily synthesized by cells in the stomach and released in
response to fasting, such that circulating levels are maximal prior
to meals and fall upon feeding (98, 99). In vivo, ghrelin is an orex-
igenic factor, increasing food intake and inducing release of GH
from the pituitary via the hypothalamus.
The ghrelin receptor, GHS-R, is expressed in osteoblastic cells,
but we found that ghrelin only weakly activated cell proliferation
in cultures of primary rat and human osteoblasts (100). Other
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FIGURE 1 | Summary – factors that mediate the positive
association between fat and bone. (A) Adipokines: leptin directly
increases osteoblast number and activity while inhibiting osteoclast
activity, producing an overall anabolic bone effect. Animal studies
produced conflicting results, some suggesting anabolic effect on bones
and others showing negative bone effects through indirect
mechanisms. Adiponectin – circulating levels of adiponectin correlate
negatively with body fat and there is strong inverse relationship
between circulating adiponectin and BMD. Adiponectin directly
increases osteoblast number and activity, whereas its effects in
osteoclasts vary in different experimental systems. The bone phenotype
of adiponectin-deficient animals varies with age. (B) Peptide hormones
secreted from pancreatic islets and from the gut in response to feeding
have direct and indirect anabolic bone effects.
groups have shown that ghrelin increases proliferation and dif-
ferentiation in cultures of animal and human osteoblastic cells
(101–105). There is also evidence for ghrelin expression and secre-
tion by osteoblast (101). The effect of ghrelin on bone was studied
in a number of animal models. Ghrelin infusion increased BMD
in rats, and a similar effect was observed in GH-deficient rats, sug-
gesting the existence of a GH-independent effect of ghrelin in bone
(102). In contrast, ghrelin knockout mice and GHS-R knockout
mice had no changes in either bone mineral content or density
in comparison to control mice (106, 107). Transgenic mice over-
expressing ghrelin in the brain and stomach showed increased food
intake and impaired glucose tolerance but otherwise had normal
body size (108). No analysis of bone metabolism was carried out
in this study.
In humans, 4 h of ghrelin infusion in healthy subjects and
post-gastrostomy patients showed no acute effects on mark-
ers of bone turnover (109). Treatment with an oral ghrelin
mimetic for 12 months was associated with a small increase in
femoral neck BMD, whereas no changes were observed in other
sites (110).
GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE
Glucose-dependent insulinotropic polypeptide or gastric inhibitory
polypeptide (GIP) is a 42 amino acid protein secreted from K-cells
of the duodenum and from the small intestine in response to
feeding, and induces insulin and glucagon secretion from the
pancreas (111).
GIP receptor is expressed in osteoblasts, osteocytes, and osteo-
clasts (95) and in vitro, GIP increases osteoblast number and
activity and inhibits osteoclast activity, suggestive of an overall
direct anabolic effect in bone (112–114). Transgenic mice over-
expressing GIP have increased bone formation, decreased bone
resorption, and increased bone mass, and a long-term study also
demonstrated reduced bone loss with aging (115,116). In addition,
administration of GIP reduces bone loss in ovariectomized mice
(112). Mice lacking the GIP receptor, who have blunted insulin
response to feeding, have low bone mass with reduced bone for-
mation and increased numbers of mature osteoclasts (117, 118).
In humans, 48 h after an intravenous bolus of GIP, there were
no significant changes in serum levels of either markers of bone
resorption or bone formation (119).
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GLUCAGON-LIKE PEPTIDES
Glucagon-like peptide-1 (GLP-1) and GLP-2 are two hormones
derived from proglucagon precursor by proteolytic cleavage. These
hormones are co-secreted from intestinal L-cells and their levels
rise rapidly after food intake. Similar to GIP, GLP-1 stimulates
insulin secretion from the pancreas, whereas GLP-2 acts in the
intestine to stimulate mucosal growth and nutrient absorption
(94, 95). A number of GLP-1 analogs are being developed as phar-
maceutical agents for the treatment of type-2 diabetes, as GLP-1
increases postprandial insulin secretion, suppresses postprandial
glucagon secretion, and delays gastric emptying (120). A small
clinical study compared the postprandial plasma concentrations of
GLP-1 and GLP-2 between a group that had previously consumed
calcium phosphate-enriched diet for 3 weeks and a control group.
The study showed that postprandial GLP-1 and GLP-2 levels were
significantly increased in the group that had calcium phosphate-
enriched diet, whereas levels of insulin and glucose showed no
differences between the groups (121).
Although GLP-1 receptor is expressed in bone marrow stromal
cells and in immature osteoblasts, it is not expressed in mature
osteoblasts and therefore it is unlikely to have direct activity in
these cells (113, 122, 123). Evidence from in vitro experiments
suggests no direct effect of GLP-1 in either osteoblasts or osteo-
clasts (124). However, GLP-1 receptors are expressed in thyroid C
cells,where GLP-1 induces postprandial calcitonin release and thus
indirect inhibition of bone resorption (124). Mice deficient of the
GLP-1 receptor have cortical osteopenia and increased osteoclast
numbers and bone resorption activity (124).
In contrast to GLP-1, GLP-2 receptors are expressed on osteo-
clasts and GLP-2 has been shown to decrease bone resorption
in vitro (125). In several human studies, administration of exoge-
nous GLP-2 reduced bone resorption, as measured by reduction
in circulating bone turnover markers whereas bone formation
markers were unaffected (119, 126, 127).
CONCLUSION
The mechanisms of communication between different tissues in
the body are very complex and the various in vitro and in vivo
experimental systems designed to investigate these mechanisms
do not always produce congruent results. In the study of the rela-
tionship between fat mass and bone mass, the most consistent
clinical observation is that body weight is positively correlated
with BMD and negatively associated with fracture risk. Of the
numerous laboratory studies of the possible mediators of the fat–
bone association, the current review focused on studies of the
direct bone effects of adipokines (summarized in Figure 1A) and
of hormones that respond to feeding (Figure 1B). Hormones
secreted in response to feeding shift bone turnover balance to
favor formation, whereas low levels of these hormones induce
bone resorption. It is likely that these responses have evolved to
promote bone mass and strength when nutrition is abundant
and to maintain calcium homeostasis in times of food short-
age. Other important physiological links between fat and bone,
which were not discussed in detail here, include their indirect
communication through the central nervous system, and the
fact that osteoblasts and adipocytes differentiate from a com-
mon mesenchymal precursor cell. In vitro studies in combination
with investigations of genetically modified animals substantially
advanced our understanding of the relationship and crosstalk
between fat and bone tissue. However, only clinical studies can
ultimately determine whether hypotheses produced using exper-
imental model systems have relevance to human physiology and
pathology.
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